A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)
奥希替尼联合或不联合雷莫芦单抗治疗酪氨酸激酶抑制剂初治的EGFR突变转移性非小细胞肺癌的多中心开放标签随机II期研究(RAMOSE试验)
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.24.00533
Le, Xiuning; Patel, Jyoti D; Shum, Elaine; Baik, Christina; Sanborn, Rachel E; Shu, Catherine A; Kim, Chul; Fidler, Mary Jo; Hall, Richard; Elamin, Yasir Y; Tu, Janet; Blumenschein, George; Zhang, Jianjun; Gibbons, Don; Gay, Carl; Mohindra, Nisha A; Chae, Young; Boumber, Yanis; Sabari, Joshua; Santana-Davila, Rafael; Rogosin, Shane; Herzberg, Benjamin; Creelan, Ben; Pellini, Bruna; Tanvetyanon, Tawee; Heeke, Simon; Hernandez, Mike; Gray, Jhanelle E; Saltos, Andreas; Heymach, John V